Baxter Healthcare Corporation secured FDA approval on August 6, 2026, for Levetiracetam in the IV formulation as part of ANDA208458, a pivotal move that will likely intensify competition and provide cost-effective alternatives to biologic therapies currently dominating the intravenous market. The expanded product portfolio is expected to broaden Baxter's patient access and optimize supply chains for hospitals managing acute seizure disorders.